Delving into the Latest Updates on Allogeneic platelet lysate(Pavlov First Saint Petersburg State Medical University) with Synapse

Overview

Basic Info

Drug Type

Blood components

Synonyms-

Target-

Action-

Mechanism-

Therapeutic Areas

Immune System DiseasesEye DiseasesOther Diseases

Active Indication

Chronic graft-versus-host diseaseKerato conjunctivitis sicca

Inactive Indication-

Originator Organization

Pavlov First Saint Petersburg State Medical University

Active Organization

Pavlov First Saint Petersburg State Medical University

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

The study evaluates the efficacy and safety of allogeneic platelet lysate eye drops in patients with severe ocular graft versus host disease refractory to conventional systemic and local treatments. The corneal staining, conjunctival hyperemia, tear film break up time,Schirmer test and ocular surface disease index will be evaluated before and after allogeneic platelet lysate treatment. The safety of allogeneic platelet lysate treatment will be also assessed.

Start Date01 Apr 2021

Sponsor / Collaborator

Pavlov First Saint Petersburg State Medical University

100 Clinical Results associated with Allogeneic platelet lysate(Pavlov First Saint Petersburg State Medical University)

Login to view more data

100 Translational Medicine associated with Allogeneic platelet lysate(Pavlov First Saint Petersburg State Medical University)

Login to view more data

100 Patents (Medical) associated with Allogeneic platelet lysate(Pavlov First Saint Petersburg State Medical University)

Login to view more data

100 Deals associated with Allogeneic platelet lysate(Pavlov First Saint Petersburg State Medical University)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic graft-versus-host disease	Phase 2	Russia	Pavlov First Saint Petersburg State Medical University	01 Apr 2021
Kerato conjunctivitis sicca	Phase 2	Russia	Pavlov First Saint Petersburg State Medical University	01 Apr 2021

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data